Table 2.
Ref.
|
Study design, Country
|
Number of HGS vs CDS
|
Technical success CDS vs HGS, %
|
Clinical success HGS vs CDS, %
|
Adverse events, HGS vs CDS, %
|
Tyberg et al[86], 2022 | Multicenter,International | 95 vs 87 | 92% vs 92%, NS | 86% vs 100%, NS | 21% vs 26%, P = 0.17 |
Minaga et al[85], 2019 | Multicenter, Japan | 24 vs 23 | 87.5% vs 82.6%, P = 0.028 | 100% vs 94.7%, P = 0.0475 | 28.6% vs 21%, P = 0.583 |
Cho et al[94], 2017 | Single Center, Korea | 21 vs 33 | 100% vs 100%, NS | 86% vs 100%, P = 0.054 | 19% vs 15%, NS |
Amano et al[93], 2017 | Single Center, Japan | 9 vs 11 | 100% vs 100%, NS | 100% vs 100%, NS | 11% vs 18%, NS |
Ogura et al[92], 2016 | Single Center, Japan | 26 vs 13 | 100% vs 100% | 92% vs 100%, P = 0.0497 | 8% vs 46%, P = 0.005 |
Guo et al[91], 2016 | Single Center, China | 7 vs 14 | 100% vs 100%, NS | 100% vs 100%, NS | 14% vs 14%, NS |
Khashab et al[90], 2016 | Multicenter,International | 61 vs 60 | 92% vs 93%, P = 0.75 | 82% vs 85%, P = 0.64 | 20% vs 13%, P = 0.37 |
Artifon et al[84], 2015 | Single Center, Brazil | 24 vs 25 | 96% vs 91% | 88% vs 70% | 20% vs 13% |
Poincloux et al[64], 2015 | Single Center, France | 66 vs 26 | 94% vs 96.7%, NS | 93.8% vs 93.1%, NS | 15% vs 7.6%, NS |
Kawakubo et al[88], 2014 | Multicenter, Japan | 20 vs 44 | 95% vs 95%, NS | 95% vs 93%, NS | 4% vs 15%, NS |
Park et al[89], 2015 | Multicenter, Korea | 20 vs 12 | 100% vs 92%, P > 0.99 | 90% vs 92%, P > 0.99 | 25% vs 33%, P = 0.044 |
Prachayakul and Aswakul[87], 2013 | Single Center, Thailand | 15 vs 6 | 93% vs 100%, NS | 93% vs 100%, NS | 0% vs 33%, NS |
Kim et al[95], 2012 | Single Center, Retrospective | 13 (9 CDS; 4 HGS) | 100% vs 75%, NS | 100% vs 50%, NS | 22% vs 50%, NS |
NS: Not significant; HGS: Hepaticogastrostomy; CDS: Choledochoduodenostomy.